MicroRNAs are tiny molecules of RNA, typically just 22 nucleotides long, that act as gene regulators inside your cells. They don’t carry instructions for building proteins the way messenger RNA does. Instead, they silence genes by latching onto messenger RNA and preventing it from being translated into protein. Humans have an estimated 2,300 distinct microRNAs, and collectively they influence the activity of a large proportion of protein-coding genes.
How MicroRNAs Were Discovered
The first microRNA, called lin-4, was found in 1993 by researchers Victor Ambros and Gary Ruvkun working with a tiny roundworm called C. elegans. They noticed that lin-4 controlled the worm’s developmental timing by binding to a specific messenger RNA and blocking its translation. For years, scientists assumed this was a quirk of worm biology. It took nearly a decade before researchers realized that microRNAs exist across virtually all animal species, plants included, and play a central role in gene regulation.
Size and Structure
Mature microRNAs are single-stranded RNA molecules ranging from 16 to 27 nucleotides, with a sharp peak at 22. About 61% of known human microRNAs are exactly 22 nucleotides long, and 96.5% fall within one nucleotide of that length. That narrow size range is remarkably consistent, a reflection of the precise molecular machinery that produces them.
Before reaching their mature form, microRNAs exist as longer precursor molecules that fold into a hairpin loop structure with a median length of 83 nucleotides. That loop is a key identifying feature: it’s how cells (and researchers) distinguish a real microRNA gene from other short RNA fragments floating around the genome.
How Cells Build a MicroRNA
MicroRNA production starts in the cell nucleus, where a gene is first transcribed into a long primary transcript. An enzyme called Drosha trims this transcript down to the hairpin-shaped precursor, which is then exported out of the nucleus into the cytoplasm. There, a second enzyme called Dicer cuts the hairpin loop off, leaving a short double-stranded fragment. One strand is selected as the mature microRNA and loaded into a protein complex. The other strand is typically discarded.
That protein complex, built around a protein called Argonaute, is the functional unit. The microRNA serves as a guide, directing the complex to messenger RNAs that carry a complementary sequence. Without the Argonaute protein, the microRNA would be too small and fragile to do anything useful on its own.
How Gene Silencing Works
The microRNA doesn’t need to match its target messenger RNA perfectly. In fact, most interactions in animal cells involve imperfect pairing. The critical region is the “seed sequence,” nucleotides 2 through 8 of the microRNA. This short stretch must pair well with a complementary site on the target messenger RNA, usually located in a region called the 3′ untranslated region, which sits downstream of the protein-coding instructions.
The seed sequence works in two steps. Nucleotides 2 through 5 make initial contact with the target. If that pairing is favorable, nucleotides 6 through 8 join in. Additional pairing further along the microRNA can stabilize the connection, but the seed is what determines whether a given messenger RNA gets targeted at all. This is why a single microRNA can regulate hundreds of different genes: any messenger RNA carrying a matching seed site is a potential target.
Once the microRNA finds its target, silencing happens through two main routes. The most common in human cells is translational repression, where the messenger RNA is blocked from being read by the cell’s protein-building machinery, specifically at the initiation step. The second route involves messenger RNA degradation: the complex recruits other proteins that strip the protective structures off the messenger RNA, exposing it to enzymes that break it down. In cases where the microRNA matches its target with near-perfect complementarity, the Argonaute protein can slice the messenger RNA directly, though this is rare in animals.
MicroRNAs in Cancer
Because microRNAs regulate so many genes, their dysfunction is tightly linked to disease, particularly cancer. Some microRNAs behave as tumor promoters (often called “oncomiRs”) by silencing genes that normally keep cell growth in check. MicroRNA-31, for example, drives lung cancer growth by suppressing two tumor-suppressor genes that would otherwise slow cell division and trigger cell death. Knocking down microRNA-31 in lung cancer cells substantially reduced their growth in a dose-dependent manner.
Other microRNAs act as tumor suppressors, and their loss can unleash cancer. The let-7 family and the miR-34 family both fall into this category. Low expression of let-7a and high expression of miR-155 are associated with poor outcomes in lung cancer patients. The miR-34 family works as part of the p53 tumor-suppression pathway, one of the body’s most important defenses against uncontrolled cell growth. When these protective microRNAs are silenced or deleted, cells lose a layer of growth control.
Circulating MicroRNAs as Diagnostic Tools
MicroRNAs aren’t confined to the cells that make them. They travel through the bloodstream packaged inside tiny membrane-bound vesicles called exosomes. The lipid shell of an exosome protects the microRNA from enzymes in the blood that would otherwise destroy it, making these molecules surprisingly stable in body fluids. Exosomal microRNAs are even more resistant to degradation during storage and freeze-thaw cycles than microRNAs inside cells, which makes them practical candidates for blood-based diagnostic tests.
This stability has opened the door to “liquid biopsy” approaches, where a simple blood draw could reveal disease. Colorectal cancer detection is one of the most studied applications. A large meta-analysis found that two circulating microRNAs, miR-21 and miR-29a, show strong diagnostic accuracy for colorectal cancer. MiR-21 achieved 83% sensitivity and 90% specificity, meaning it correctly identified most cancer cases while rarely flagging healthy people. MiR-29a performed nearly as well, with 72% sensitivity and 90% specificity. These numbers suggest circulating microRNAs could eventually complement or reduce the need for more invasive screening methods.
Cell-to-Cell Communication
Beyond diagnosis, exosome-carried microRNAs serve a biological purpose: they allow cells to communicate. A cell can package specific microRNAs into exosomes and release them into the surrounding fluid, where they travel to distant cells and alter gene expression upon arrival. The sorting process isn’t random. Specific proteins inside the cell recognize sequence motifs on certain microRNAs and direct them into outgoing exosomes. This means cells can selectively export microRNAs to influence the behavior of other cells, including, in the case of cancer, promoting tumor growth in distant tissues.
MicroRNA-Based Therapies
The idea of using microRNAs as medicine is straightforward in concept: deliver a synthetic microRNA to restore a missing tumor suppressor, or use an inhibitor molecule to block a harmful oncomiR. In practice, the field has been slow to deliver. No microRNA-based drug has reached Phase III clinical trials or received FDA approval. Several early candidates were terminated due to toxicity problems. One of the furthest along was lademirsen, an inhibitor of miR-21 tested in Phase II trials for Alport syndrome, a genetic kidney disease. That trial has completed, but the broader pipeline remains thin.
The challenges are significant. Delivering a tiny RNA molecule to the right tissue without triggering immune reactions or off-target effects is difficult. Because a single microRNA can regulate hundreds of genes simultaneously, blocking or mimicking one carries the risk of unintended consequences in tissues you weren’t aiming for. These hurdles haven’t killed interest in the approach, but they explain why microRNA diagnostics are currently closer to clinical reality than microRNA therapeutics.